• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina...
Source: International Heart Journal - July 13, 2022 Category: Cardiology Authors: Yan Hao Yu-Lin Yang Yong-Chao Wang Jian Li Source Type: research

Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study
ConclusionsPatients undergoing a coronary revascularization procedure who received moderate-intensity statins plus ezetimibe showed similar rates of major adverse cardiovascular events as patients who received high-intensity statins.
Source: Cardiovascular Drugs and Therapy - September 17, 2021 Category: Cardiology Source Type: research

Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarc-tion Patients with Primary Percutaneous Coronary Intervention.
CONCLUSION: The results mentioned above suggested that pitavastatin combined with ezetimibe was an effective approach to STEMI patients with non-IRA disease undergoing primary PCI. The results obtained in this study have provided a novel way for the treatment of STEMI patients with non-IRA disease undergoing primary PCI. PMID: 32598255 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - June 28, 2020 Category: Biotechnology Authors: Zhao B, Li GP, Peng JJ, Ren LH, Lei LC, Ye HM, Wang ZY, Zhao S Tags: Curr Pharm Biotechnol Source Type: research

Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention.
Conclusions: Baseline serum Lp(a) can be used to predict MACEs in patients after PCI treatment, which was independent of LDL-C. PMID: 31749864 [PubMed]
Source: Archives of Medical Science - November 23, 2019 Category: General Medicine Tags: Arch Med Sci Source Type: research

Pages: 1  2